Achmea Investment Management B.V. Has $18.24 Million Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Achmea Investment Management B.V. boosted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 61.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,180 shares of the biotechnology company's stock after purchasing an additional 22,434 shares during the period. Achmea Investment Management B.V. owned approximately 0.13% of United Therapeutics worth $18,243,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Parallel Advisors LLC lifted its stake in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 30 shares during the last quarter. Signaturefd LLC lifted its holdings in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after acquiring an additional 30 shares during the last quarter. Anchor Investment Management LLC boosted its stake in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC grew its holdings in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its position in shares of United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after purchasing an additional 33 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $3.08 during trading on Monday, hitting $287.35. The company had a trading volume of 396,954 shares, compared to its average volume of 445,911. United Therapeutics Corporation has a 52 week low of $250.60 and a 52 week high of $417.82. The business's 50-day moving average is $301.12 and its 200 day moving average is $324.60. The company has a market cap of $12.96 billion, a P/E ratio of 11.47, a PEG ratio of 6.22 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same quarter last year, the company posted $6.17 EPS. United Therapeutics's revenue for the quarter was up 17.2% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer now owns 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director now directly owns 4,883 shares in the company, valued at $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,681 shares of company stock valued at $27,319,919 over the last ninety days. Corporate insiders own 10.30% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several analyst reports. UBS Group dropped their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $386.15.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.